Top

Published in:

01-12-2020 | Human Papillomavirus | Original research

Head and neck tumors angiogenesis imaging with ⁶⁸Ga-NODAGA-RGD in comparison to ¹⁸F-FDG PET/CT: a pilot study

Authors: Steve Durante, Vincent Dunet, François Gorostidi, Periklis Mitsakis, Niklaus Schaefer, Judith Delage, John O. Prior

Published in: EJNMMI Research | Issue 1/2020

Abstract

Background

Angiogenesis plays an important role in head and neck squamous cell carcinoma (HNSCC) progression. This pilot study was designed to compare the distribution of ⁶⁸Ga-NODAGA-RGD PET/CT for imaging α_vβ₃ integrins involved in tumor angiogenesis to ¹⁸F-FDG PET/CT in patients with HNSCC.

Material and methods

Ten patients (aged 58.4 ± 8.3 years [range, 44–73 years], 6 males, 4 females) with a total of 11 HNSCC were prospectively enrolled. Activity mapping and standard uptake values (SUV) from both ⁶⁸Ga-NODAGA-RGD and ¹⁸F-FDG PET/CT scans were recorded for primary tumor and compared with the Wilcoxon signed-rank test. The relation between the SUV of both tracers was assessed using the Spearman correlation.

Results

All HNSCC tumors were visible with both tracers. Quantitative analysis showed higher ¹⁸F-FDG SUV_max in comparison to ⁶⁸Ga-NODAGA-RGD (14.0 ± 6.1 versus 3.9 ± 1.1 g/mL, p = 0.0017) and SUV_mean (8.2 ± 3.1 versus 2.0 ± 0.8 g/mL, p = 0.0017). Both ¹⁸F-FDG and ⁶⁸Ga-NODAGA-RGD uptakes were neither correlated with grade, HPV status nor p16 protein expression (p ≥ 0.17).

Conclusion

All HNSCC tumors were detected with both tracers with higher uptake with ¹⁸F-FDG, however. ⁶⁸Ga-NODAGA-RGD has a different spatial distribution than ¹⁸F-FDG bringing different tumor information.

Trial registration

NCT, NCT02666547. Registered 12.8.2012.

Mirghani H, Bellera C, Delaye J, Dolivet G, Fakhry N, Bozec A, et al. Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiol. 2019;61:89–94. https://doi.org/10.1016/j.canep.2019.05.007.CrossRefPubMed

Broglie MA, Stoeckli SJ, Sauter R, Pasche P, Reinhard A, de Leval L, et al. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery. Head Neck. 2017;39:2004–15. https://doi.org/10.1002/hed.24865.CrossRefPubMed

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301. https://doi.org/10.1200/JCO.2011.36.4596.CrossRefPubMedPubMedCentral

Escott EJ. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiol Clin North Am. 2013;51:881–93. https://doi.org/10.1016/j.rcl.2013.05.002.CrossRefPubMed

Helsen N, Van den Wyngaert T, Carp L, De Bree R, VanderVeken OM, De Geeter F, et al. Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04710-4.

Rohde M, Dyrvig AK, Johansen J, Sorensen JA, Gerke O, Nielsen AL, et al. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2014;50:2271–9. https://doi.org/10.1016/j.ejca.2014.05.015.CrossRefPubMed

Van den Wyngaert T, Helsen N, Carp L, Hakim S, Martens MJ, Hutsebaut I, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in locally advanced head-and-neck squamous cell cancer: the ECLYPS study. J Clin Oncol. 2017;35:3458–64. https://doi.org/10.1200/JCO.2017.73.5845.CrossRefPubMed

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6. https://doi.org/10.1158/1078-0432.CCR-07-0528.CrossRefPubMed

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.PubMed

10.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942–9. https://doi.org/10.1158/1078-0432.CCR-06-0266.CrossRefPubMed

11.

Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861–70. https://doi.org/10.1215/15228517-2009-024.CrossRefPubMedPubMedCentral

12.

Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008;49:255–9. https://doi.org/10.2967/jnumed.107.045526.CrossRefPubMed

13.

Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies - a review. J Adv Res. 2017;8:591–605. https://doi.org/10.1016/j.jare.2017.06.006.CrossRefPubMedPubMedCentral

14.

Kong DH, Kim MR, Jang JH, Na HJ, Lee S. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci. 2017;18. https://doi.org/10.3390/ijms18081786.

15.

Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741–8. https://doi.org/10.2967/jnumed.107.040378.CrossRefPubMed

16.

Gnesin S, Mitsakis P, Cicone F, Deshayes E, Dunet V, Gallino AF, et al. First in-human radiation dosimetry of (68)Ga-NODAGA-RGDyK. EJNMMI Res. 2017;7:43. https://doi.org/10.1186/s13550-017-0288-x.CrossRefPubMedPubMedCentral

17.

Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S126–38. https://doi.org/10.1007/s00259-011-2028-1.CrossRefPubMed

18.

Zhai C, Franssen GM, Petrik M, Laverman P, Summer D, Rangger C, et al. Comparison of Ga-68-labeled fusarinine C-based multivalent RGD conjugates and [(68)Ga]NODAGA-RGD-in vivo imaging studies in human xenograft tumors. Mol Imaging Biol. 2016;18:758–67. https://doi.org/10.1007/s11307-016-0931-3.CrossRefPubMedPubMedCentral

19.

Van Der Gucht A, Pomoni A, Jreige M, Allemann P, Prior JO. 68Ga-NODAGA-RGDyK PET/CT imaging in esophageal cancer: first-in-human imaging. Clin Nucl Med. 2016;41:e491–e2. https://doi.org/10.1097/RLU.0000000000001365.CrossRef

20.

Haubner R, Finkenstedt A, Stegmayr A, Rangger C, Decristoforo C, Zoller H, et al. [(68)Ga]NODAGA-RGD - metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur J Nucl Med Mol Imaging. 2016;43:2005–13. https://doi.org/10.1007/s00259-016-3396-3.CrossRefPubMedPubMedCentral

21.

Isal S, Pierson J, Imbert L, Clement A, Collet C, Pinel S, et al. PET imaging of (68)Ga-NODAGA-RGD, as compared with (18)F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma. EJNMMI Res. 2018;8:51. https://doi.org/10.1186/s13550-018-0405-5.CrossRefPubMedPubMedCentral

22.

Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39:777–84. https://doi.org/10.1016/j.nucmedbio.2012.02.006.CrossRefPubMed

23.

Liu JF, Deng WW, Chen L, Li YC, Wu L, Ma SR, et al. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Mol Carcinog. 2018;57:429–39. https://doi.org/10.1002/mc.22767.CrossRefPubMed

24.

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, et al. [68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303–12. https://doi.org/10.1007/s00259-011-1778-0.CrossRefPubMed

25.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, et al. Imaging integrin alphavbeta3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014;55:281–6. https://doi.org/10.2967/jnumed.113.129668.CrossRefPubMed

26.

Okami K. Clinical features and treatment strategy for HPV-related oropharyngeal cancer. Int J Clin Oncol. 2016;21:827–35. https://doi.org/10.1007/s10147-016-1009-6.CrossRefPubMed

27.

Terry SY, Abiraj K, Lok J, Gerrits D, Franssen GM, Oyen WJ, et al. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts? J Nucl Med. 2014;55:1849–55. https://doi.org/10.2967/jnumed.114.144394.CrossRefPubMed

28.

Chen SH, Wang HM, Lin CY, Chang JT, Hsieh CH, Liao CT, et al. RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: results from a pilot study. Eur J Nucl Med Mol Imaging. 2016;43:1621–9. https://doi.org/10.1007/s00259-016-3345-1.CrossRefPubMed

Title: Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study
Authors: Steve Durante
Vincent Dunet
François Gorostidi
Periklis Mitsakis
Niklaus Schaefer
Judith Delage
John O. Prior
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keyword: Human Papillomavirus
Published in: EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-020-00638-w

At a glance: The STEP trials

Springer Medicine

Head and neck tumors angiogenesis imaging with ⁶⁸Ga-NODAGA-RGD in comparison to ¹⁸F-FDG PET/CT: a pilot study

Abstract

Background

Material and methods

Results

Conclusion

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Material and methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

A novel PET tracer 18F-deoxy-thiamine: synthesis, metabolic kinetics, and evaluation on cerebral thiamine metabolism status

Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics

Correction to: Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model

Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients

Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer